Searchable abstracts of presentations at key conferences in oncology

oa0001p029 | (1) | PacRim7

Translation of the ERα-PR crosstalk story to the clinic (the PIONEER study), and further preclinical exploration of the diverse role of progestins in ER-positive breast cancer

Kumar Sanjeev S , Siersbaek Rasmus , Nagarajan Sankari , Provenzano Elena , Caldas Carlos , Pantziarka Pan , Baird Richard D , Carroll Jason

Background: Published preclinical findings from our lab (Cambridge Institute, CRUK) provided new insights into the functional ‘cross-talk’ between the oestrogen receptor alpha (ERα) and the progesterone receptor (PR) in breast cancer (Mohammed et al., Nature, 2015). Addition of a PR agonist to anti-oestrogens directly modifies ERα chromatin binding and the transcriptional response in breast cancer cells, and is anti-proliferative in vitro ...

oa0001p016 | (1) | PacRim7

AR chromatin binding is reprogrammed in the absence of FOXA1 in ER- breast cancers

Denis Iza , Selth Luke A , Robinson Jessica LL , Mohammed Hisham , Carroll Thomas , Brown Gordon D , Neal David E , Carroll Jason S , Tilley Wayne D , Hickey Theresa E

Introduction: 75% of breast cancers (BCa) are driven by the estrogen receptor α (ER+). Tumours lacking ER (ER-) are more aggressive and have the poorest prognosis. The androgen receptor (AR) is also widely expressed in BCa (90% of primary tumours). FOXA1 is a pioneer factor required for oncogenic AR signalling in PCa but its role in AR signaling in ER-BCa is not clear. We previously showed that cell growth is increased when FOXA1 is overexpressed in AR-driven PCa and BCa ...

oa0001p047 | (1) | PacRim7

IL6/STAT3 co-opts ER regulatory elements to drive metastasis in breast cancer

Siersbaek Rasmus , Scabia Valentina , Chernukhin Igor , Papachristou Eva , Broome Rebecca , Green Andrew R , Joosten Stacey , Kumar Sanjeev , Alvarez Ruben , Nagarajan Sankari , Glont Silvia , Omarjee Soleilmane , Aitken Sarah , Kishore Kamal , Rakha Emad , D'Santos Clive , Zwart Wilbert , Russell Alasdair , Brisken Cathrin , Carroll Jason S

Interleukin 6 (IL6) signaling has been associated with an aggressive and metastatic phenotype in multiple solid tumors including breast cancer, but its mechanism of action in mediating tumor progression and treatment response is not clear. By exploiting a clinically relevant intraductal xenograft model of estrogen receptor positive (ER+) breast cancer, we demonstrate that IL6 increases both primary tumor growth and distant metastases. By integrating pre-clinical models and cli...